Frost Bank and Shred-It to host 12 document shredding events around the Austin area
If you've been wondering what to do with that old stack of bills, bank statements, or medical records, this might be the perfect time to pull them out of your files — or that box at the bottom of the stack in your closet.
From now until early May, Frost Bank will host shredding events at select Frost Financial Centers. No sign-up or credentials are required, allowing Austinites to have their sensitive documents shredded by Shred-It.
Participants can bring up to 10 containers of paper products to be shredded, without needing to remove paper clips or staples. Paper documents can remain in envelopes. However, the shred events cannot accommodate items like cardboard boxes, X-rays, CDs, DVDs, hard drives or pill bottles.
Last year, the same initiative allowed Austinites to shred 271 tons of paper. Frost estimates that this saved 4,677 trees, 828 cubic yards of landfill and 563 barrels of oil. The initiative is a tradition for the company and is designed to enhance privacy and security.
The event is now in its 10th year, according to Frost, and is held during tax season to accommodate the high number of financial documents that often need to be discarded after filing season.
"We partner with a local shredding company and invite the public to bring their documents," said Frost Bank Senior Vice President Bill Day. "Some of the events also can dispose of old computers, phones and other electronics, but many are paper only. These events always are free and open to the public."
The events will take place at these dates and locations:
Stassney Financial Center, Friday, 9 a.m. to noon
Lake Travis Financial Center, April 11, 10 a.m. to 4 p.m.
Four Points Financial Center, April 16, 1-4 p.m.
West Lake Hills Financial Center, April 17, 10 a.m. to 1 p.m.
Tarrytown Financial Center, April 22, 11 a.m. to 2 p.m.
Northwest Hills Financial Center, April 23, noon to 3 p.m.
Easton Park Financial Center, April 24, 1-4 p.m.
Kyle Financial Center, April 25, noon to 3 p.m.
Bastrop Financial Center, April 26, 9 a.m. to noon
North Austin Financial Center, April 28, 11 a.m. to 2 p.m.
La Frontera Financial Center, April 30, 1-4 p.m.
Georgetown North Financial Center, May 7, 10 a.m. to 1 p.m.
Beck Andrew Salgado covers trending topics in the Austin business ecosystem for the American-Statesman. To share additional tips or insights with Salgado, email Bsalgado@gannett.com.
This article originally appeared on Austin American-Statesman: Frost Bank and Shred-It to host 12 document shredding events in Austin
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
China consumer prices slump again, deepening deflation worries as demand stays weak
China's consumer prices fell for a fourth consecutive month in May, as Beijing's stimulus measures appear insufficient to boost domestic consumption while trade tensions simmer. The consumer price index fell 0.1% from a year earlier, according to data from the National Bureau of Statistics released Monday, compared with the median estimate for a 0.2% decline among analysts polled by Reuters. The CPI slipped into negative territory in February, falling 0.7% from a year ago, and continued to post year-on-year declines of 0.1% in March and April. Separately, deflation in the country's factory-gate or producer prices deepened, falling 3.3% from a year earlier in May, a sharper decline than analysts' expectations for a 3.2% drop. The wholesale prices have remained in deflationary territory since October 2022, according to LSEG data. On May 7, Chinese top financial regulators unleashed a flurry of policy steps aimed at bolstering the country's tariff-hit economy. China's central bank cut the key interest rates by 10 basis points to historic-low levels and lowered the reserve requirement ratio, which determines the amount of cash banks must hold in reserves, by 50 basis points. U.S. President Donald Trump had ratcheted up tariffs on Chinese goods to prohibitive levels of 145%, prompting Beijing to retaliate with duties and other restrictive measures, such as export controls on its critical minerals. On May 12, the economy got a relief after U.S. and China struck a preliminary deal in Geneva, Switzerland that led both sides to drop a majority of tariffs. Washington lowered its levies on Chinese goods to 51.1% while Beijing dropped taxes on American imports to 32.6%, according to think tank Peterson Institute for International Economics, allowing some room for both sides to negotiate a broader deal.
Yahoo
an hour ago
- Yahoo
Frost & Sullivan: iRegene Therapeutics Honored as "2025 Forbes China Leading Enterprises in Industry Development"
Shanghai, China--(Newsfile Corp. - June 8, 2025) - Recently, The "2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor," jointly organized by Frost & Sullivan and Forbes China, was successfully held at Regent Shanghai on The Bund. Amid the global trend of industrial innovation, the results of the "2025 Pioneer Innovators in Industry Development" selection jointly initiated by Forbes China and Frost & Sullivan were officially announced. iRegene Therapeutics was honored as one of Forbes China's 2025 Leading Enterprises in Industry Development. iRegene is pioneering the future of regenerative medicine with its AI-powered, chemically induced cell therapy platform. By combining cutting-edge technology, a robust R&D ecosystem, and a globally experienced leadership team, iRegene is redefining allogeneic therapies to make them safer, more effective, and broadly accessible. This recognition highlights iRegene's continued leadership in innovation and its commitment to transforming patient care through next-generation regenerative therapies. iRegene Therapeutics Honored as 2025 Forbes China Leading Enterprises in Industry Development Aroop Zutshi, Global Managing Partner and Executive Board Director of Frost & Sullivan, and Junyi Guo, General Manager of Business Operations at Forbes China, jointly presented the 2025 Forbes China Leading Enterprises in Industry Development award. Dr. Jun Wei, Chairman of iRegene Therapeutics, was invited to attend the gala. AI-Driven Chemical-Induced Cell Therapy: Reshaping the Future of Accessible Cell Therapy Since its establishment in 2017, iRegene Therapeutics has remained committed to addressing unmet clinical needs through the development of next-generation cell therapies. With a focus on chemically induced, universal cell therapy products, iRegene aims to deliver transformative treatments for patients with currently incurable diseases. iRegene Therapeutics has a proprietary, AI-based platform for screening chemical compounds to modify specific cellular functions. The platform leverages induced pluripotent stem cells (iPSCs) to enhance treatment potential. By combining compounds to form a chemically induced culture medium, the "AI+Chem" platform can efficiently and precisely reprogram or optimize a cell's fate and function, thereby enhancing the clinical capabilities of cell therapies. With a focus on the chemical induction system, iRegene has developed a comprehensive research and development (R&D) ecosystem and an international patent system that spans the industry. This ecosystem combines the discovery of 'cell fate determinants', the screening of chemical inducers and the validation of cellular function. The system does not use viral vector construction or transgenic methods; the straightforward CMC procedure is cost-efficient. Furthermore, cell transformation and functional optimization are entirely driven by the cells' natural genetic makeup. Transformation is synchronous under chemically enhanced regulation, eliminating the risk of genetic modification. iRegene's pioneering platform has been proven through the positive outcomes of the Phase I clinical trial. In addition, iRegene's executive team has an international perspective, with all members having successful overseas experience in their specialized fields. CEO Dr Wei Jun is a leading expert in regenerative medicine and the induced pluripotent stem cell (iPSC) technology, bringing strategic leadership to the company. Chief Medical Officer Dr Cai Meng has extensive experience taking innovative therapies from discovery through clinical development, while Chief Quality Officer Ren Xiang is a senior regulatory expert who provides solid support from IND approval to NDA clearance in China, the US, and other countries. Executive Vice President Emmanuel Montet, formerly Vice President of the Asia-Pacific region at Ipsen, now leads iRegene's global business development and international strategy. To accelerate global clinical translation and commercialization, iRegene places great emphasis on the philosophy of 'cooperation and mutual benefit'. At the end of 2021, iRegene entered a long-term collaboration with Danaher Corporation to co-develop next-generation platforms for clinical application. Under this partnership, Danaher will play an active role in developing multi-directional platforms for future iRegene Therapeutics projects. This will involve supplying advanced detection instruments and technical resources relating to life sciences research, the development of effective compounds and screening, multi-omics cell mechanism research, and multi-substance screening. Danaher will help iRegene Therapeutics to enhance the efficiency of platform construction and its ability to deliver practical solutions. Danaher will also support iRegene Therapeutics in developing distinctive, innovative drug pipelines and establishing a research and production base. This strategic cooperation has recently been elevated to the iRegene - Danaher Joint Innovation Center, which is the world's first "Joint Innovation Center for Chemically Induced Therapies and Microphysiology Systems". The center will focus on integrating artificial intelligence (AI)-driven chemically induced cell therapy R&D with microphysiology systems technology. It is committed to accelerating the clinical translation and application of innovative therapies, and providing patients globally with more precise and effective treatment solutions for diseases. Danaher will fully support iRegene Therapeutics' future planning and development, aiming to jointly advance innovative development in China's life sciences research. iRegene's breakthrough technology platform, strategic advantages and dedicated team have secured continuous support from several leading venture capital firms, with cumulative financing reaching nearly 400 million RMB (55.5 million USD). The company is advancing multiple programs through clinical development, targeting a win-win situation for its products and the capital markets alike, while providing patients around the world with next-generation chemically induced cell therapies that can genuinely reverse disease progression. About iRegene Therapeutics iRegene Therapeutics is a biotechnology company committed to becoming a global leader in universal chemical-induced cell therapy. As one of the first companies to harness AI and + chemical induction for the specific functional modification of cells, iRegene offers a safer, more scalable, and cost-effective alternative to traditional gene or cell therapies. Its pipeline targets diseases with high unmet need, including neurodegenerative disorders such as Parkinson's disease and blindness. Through pioneering science, strategic global partnerships, and a visionary leadership team, iRegene is reshaping the future of regenerative medicine - making advanced therapies accessible to patients worldwide. In August 2023, the NMPA approved the commencement of Phase I clinical trials for iRegene's first product: 'Human Dopaminergic Precursor Cell, NouvNeu001'. This product was developed using the 'AI+ Chem' platform. This made it the world's first chemically induced pluripotent stem cell (iPSC)-derived therapy to enter clinical trials. In June 2024, it was approved by the U.S. FDA for overseas clinical trials. Even more groundbreakingly, in March 2024, iRegene's 'Chemical Induction Platform' became the first system ever to be granted exemption by the FDA. The company's second product, NouvNeu003, which is intended for the treatment of early-onset Parkinson's disease, received NMPA approval in December 2023 and entered Phase I clinical trials. Both NouvNeu001 and NouvNeu003 have now completed Phase I trials. The Phase I results demonstrate good safety, tolerability, and encouraging efficacy in improving motor and non-motor symptoms. The Phase II trial for NouvNeu001 began in April 2025. In parallel, iRegene's first-in-class ophthalmic therapy, was granted Orphan Drug Designation (ODD) by the U.S. FDA in March 2024. Media Contact Company Name: Frost & SullivanWebsite: PR@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
How Much the Average Homeowner Has in Savings vs. the Average Renter
Housing is the largest expense for the average American consumer. The more people have to spend on housing, the less money they have available to invest, save, or spend in other categories. But does owning your home instead of renting affect how much you have in your savings account? And is it the best financial decision for you right now? Check Out: Try This: The Federal Reserve's most recent Survey of Consumer Finances suggests the answer is yes. Here's how the average renter's savings compares to those of the average homeowner. The Survey of Consumer Finances data goes back to 1989, and since then, homeowners have always had more in savings than renters, on average. However, the gap between homeowners' and renters' savings has been growing. For example, in 1995, on average, homeowners had around twice as much saved as renters. Now, homeowners have five times more in savings than the average renter. Up Next: The most recent national data estimates that the average renter had $16,930 in savings. That includes all money in savings, checking, emergency funds and money market accounts. Though rent amounts will vary greatly depending on your location and size of your space, the current national average rent in the United States ranges from about $1,625 to $2,100 per month, which is a 1.1% increase compared to last year. By comparison, the average homeowner had $85,430 in savings, which is nearly $70,000 more than the average renter. That's a big difference when it comes to what you're able to allocate for emergency savings and retirement accounts. However, buying a home is not an option for the average savings, as the national average house price in the U.S. for Q1 2025 is $503,800, whereas the median sales price in the same period was $416,900, Perhaps counterintuitively, renting is often less expensive than owning a home. In the largest 50 metropolitan areas in the U.S., the median cost of renting is currently $1,398. This figure has been trending modestly downward since the second half of 2022, and represents the middle ground, with half of rents being higher and half lower, so it is quite subject to fluctuations. The median home price is currently $416,900, and the average mortgage rate is 6.97%, per the Fed. With a 20% down payment and a 30-year fixed-rate mortgage, your monthly mortgage payment likely ranges from $2,167 to $2,715, excluding taxes and insurance. High interest rates are likely driving most of the higher costs of homeownership. If mortgage rates go down as expected, monthly mortgage payments will decrease. However, despite the higher costs, homeowners still save more than renters. So why is there such a big difference between how much renters save and how much homeowners do? One explanation is that rental prices continually increase while the cost of owning a home stays relatively stable after the purchase. Say you buy a new home with a 30-year fixed-rate mortgage. Your monthly housing costs will be stable for the 30 years of the loan. After you've paid off your mortgage, you'll have to pay only taxes, insurance and maintenance. Unexpected maintenance costs, such as roof damage or broken pipes, can eat into a homeowner's savings, whereas renters don't have to pay for these costs out of pocket since they're the landlord's responsibility. However, renters do have to cover rising rental rates nearly every year. Since 2019, rent prices have increased by around 19% nationwide. Rising rent prices can take up larger and larger chunks of renters' budgets. As their housing costs increase, they have less money to put toward savings and other financial goals. By comparison, homeowners have more of their income to put into savings after paying off their mortgages. The bottom line is that if you're a renter hoping to put more in your bank account, you should try these money-saving strategies: Pay off debt with high interest rates: High-interest debt can prevent you from building your savings. Start by paying off any loans with high interest rates, like credit card debt. Live with a roommate: Splitting your housing costs with a roommate will give you extra money each month to put toward savings. Renegotiate with your landlord: When your lease is up and it's time to sign a new one, negotiate your monthly payment. If your landlord charges more than the market rate, it may be worth moving to a more affordable home. Finally, remember to put at least some of your savings into a high-yield savings account so you can grow your money. Caitlyn Moorhead contributed to the reporting for this article. More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard How Much Money Is Needed To Be Considered Middle Class in Every State? 10 Unreliable SUVs To Stay Away From Buying This article originally appeared on How Much the Average Homeowner Has in Savings vs. the Average Renter Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
